Latest Period
Q4 2025
Security Snapshot
X4 Pharmaceuticals, Inc - Common Stock (XFOR) Institutional Ownership
CUSIP: 98420X202
13F Institutional Holders and Ownership History from Q1 2025 to Q1 2026
Institutions Reporting
75
Shares (Excl. Options)
85,919,846
Price
$4.00
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- XFOR on Nasdaq
- Shares outstanding
- 87,101,353
- Price per share
- $4.10
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 85,919,846
- Total reported value
- $343,681,474
- % of total 13F portfolios
- 0%
- Share change
- +57,015,275
- Value change
- +$228,817,038
- Number of holders
- 75
- Price from insider filings
- $4.10
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- XFOR - X4 Pharmaceuticals, Inc - Common Stock is tracked under CUSIP 98420X202.
- 75 institutions reported positions in Q4 2025.
- 12 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 75 to 7 between Q4 2025 and Q1 2026.
- Reported value moved from $343,681,474 to $1,152,217.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 75 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 98420X202?
CUSIP 98420X202 identifies XFOR - X4 Pharmaceuticals, Inc - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 98420X202:
Significant Owners of X4 Pharmaceuticals, Inc - Common Stock (XFOR) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Empery Asset Management, LP | 10% | 0% | $35,180,748 | +$25,462,897 | 9,043,894 | +262% | Empery Asset Management, LP | 31 Dec 2025 |
| MORGAN STANLEY | 10% | +8.9% | $29,940,219 | +$2,318,051 | 8,884,338 | +8.4% | Morgan Stanley | 28 Feb 2026 |
| FMR LLC | 9.7% | $33,996,400 | 8,499,100 | FMR LLC | 31 Oct 2025 | |||
| Saturn V Capital Management LP | 7.4% | $25,026,241 | 6,433,481 | Saturn V Capital Management LP | 24 Oct 2025 | |||
| PERCEPTIVE ADVISORS LLC | 7.6% | $20,980,760 | 6,064,680 | Perceptive Advisors LLC | 27 Oct 2025 | |||
| Trails Edge Capital Partners, LP | 5.8% | -41% | $20,333,894 | +$11,320,168 | 5,227,222 | +126% | Trails Edge Capital Partners, LP | 31 Dec 2025 |
| Growth Equity Opportunities 18 VGE, LLC | 6.2% | -38% | $17,496,802 | +$9,734,867 | 5,057,610 | +125% | Growth Equity Opportunities 18 VGE, LLC | 27 Oct 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 3.9% | -60% | $13,272,653 | +$4,544,819 | 3,411,993 | +52% | BVF PARTNERS L P/IL | 31 Dec 2025 |
| Coastlands Capital LP | 10% | 0% | $7,773,911 | +$37,418 | 2,491,638 | +0.48% | Coastlands Capital LP | 03 Oct 2025 |
| Nantahala Capital Management, LLC | 2.8% | -72% | $9,528,431 | +$798,030 | 2,449,468 | +9.1% | Nantahala Capital Management, LLC | 31 Dec 2025 |
| Deep Track Capital, LP | 10% | $4,568,300 | 2,366,995 | Deep Track Capital, LP | 12 Aug 2025 | |||
| BlackRock, Inc. | 3% | $377,954 | 179,125 | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Dec 2025, 75 institutional investors reported holding 85,919,846 shares of X4 Pharmaceuticals, Inc - Common Stock (XFOR). This represents 99% of the company’s total 87,101,353 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of X4 Pharmaceuticals, Inc - Common Stock (XFOR) together control 96% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Empery Asset Management, LP | 10% | 8,951,105 | 0% | 32% | $35,804,420 |
| FMR LLC | 9.8% | 8,499,100 | 0% | $33,996,400 | |
| MORGAN STANLEY | 9.4% | 8,208,015 | +220072% | 0% | $32,832,060 |
| Bain Capital Life Sciences Investors, LLC | 9.1% | 7,967,454 | +227% | 2.4% | $31,869,816 |
| PERCEPTIVE ADVISORS LLC | 7.2% | 6,314,452 | 0.46% | $25,257,808 | |
| Saturn V Capital Management LP | 6.7% | 5,800,530 | 4.3% | $23,202,120 | |
| Deep Track Capital, LP | 5.8% | 5,013,661 | +347% | 0.46% | $20,054,644 |
| Kalehua Capital Management LLC | 4.3% | 3,722,840 | 0% | 15% | $14,891,360 |
| VANGUARD GROUP INC | 3.9% | 3,423,662 | +734% | 0% | $13,694,648 |
| BRAIDWELL LP | 3.9% | 3,368,904 | 0.43% | $13,475,616 | |
| Blackstone Inc. | 3.1% | 2,681,922 | 0.05% | $10,727,688 | |
| Rosalind Advisors, Inc. | 3% | 2,605,920 | +69% | 4% | $10,423,680 |
| Trails Edge Capital Partners, LP | 3% | 2,571,478 | 0% | 2.5% | $10,285,912 |
| Nantahala Capital Management, LLC | 2.8% | 2,449,468 | +9.9% | 0.58% | $9,797,872 |
| BVF INC/IL | 2.6% | 2,233,742 | 0% | 0.3% | $8,934,968 |
| SAMSARA BIOCAPITAL, LLC | 2.3% | 1,960,000 | 0.81% | $7,840,000 | |
| Siren, L.L.C. | 1.7% | 1,500,000 | 0.18% | $6,000,000 | |
| BlackRock, Inc. | 1.4% | 1,226,808 | +1881% | 0% | $4,907,232 |
| Woodline Partners LP | 1.1% | 1,000,855 | 0.02% | $4,003,420 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 940,447 | +1081% | 0% | $3,763,835 |
| STEMPOINT CAPITAL LP | 1% | 898,465 | +62% | 0.62% | $3,593,860 |
| GOLDMAN SACHS GROUP INC | 0.96% | 831,890 | 0% | $3,327,560 | |
| Point72 Asset Management, L.P. | 0.93% | 808,154 | +3630% | 0.01% | $3,232,616 |
| Stonepine Capital Management, LLC | 0.68% | 593,573 | -44% | 1.9% | $2,374,292 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.41% | 357,387 | 0.21% | $1,429,548 |
Institutional Holders of X4 Pharmaceuticals, Inc - Common Stock (XFOR) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 280,011 | $1,152,217 | +$1,083,400 | $4.13 | 7 |
| 2025 Q4 | 85,919,846 | $343,681,474 | +$228,817,038 | $4.00 | 75 |
| 2025 Q3 | 13,652,105 | $46,690,414 | +$40,048,768 | $3.42 | 40 |
| 2025 Q2 | 2,150,633 | $4,086,190 | +$4,064,925 | $1.90 | 49 |
| 2025 Q1 | 83,045 | $20,007 | +$20,007 | $0.24 | 2 |